

Osteogenesis Imperfecta and Bone Fragility Gene Panel (OIBFG) Prior Authorization Ordering Instructions

Mayo Clinic Laboratories is pleased to offer prior authorization services and third party billing on our Osteogenesis Imperfecta and Bone Fragility Gene Panel, Varies (OIBFG). To utilize our prior authorization services on this test, you must follow the process as outlined below.

Ordering and Prior Authorization Process

Mayo Clinic Laboratories utilizes an extract and hold process for prior authorization. To order OIBFG with prior authorization services, complete this document as instructed below by insurance type. You must order test code OIBFG and send the completed paperwork in with the sample. The receipt of the paperwork and sample at Mayo Clinic Laboratories will trigger the extract and hold process and generate a request to the MCL Business Office to verify your patient's insurance coverage for the testing and begin any additional prior authorization services.

If the expected patient out-of-pocket expense is \$200 or less after prior authorization services, Mayo Clinic Laboratories will automatically proceed with OIBFG testing. If the expected patient out-of-pocket expense is greater than \$200, Mayo Clinic Laboratories will seek approval from the client contact listed on the Patient Demographics and Third Party Billing Information form **before proceeding** with OIBFG testing. The MCL Business Office offers interest-free payment plans on balances over \$200.

Commercial Insurance

For patients with commercial insurance, complete the following, staple them together and send with the specimen:

- Patient Demographics and Third Party Billing Information form (required)
- Letter of Medical Necessity (required)
- · Copy of front and back of insurance card (if available)

Note: The Advanced Beneficiary Notice of Noncoverage (ABN) form is not required for commercial insurance-covered patients.

Medicare

For patients with Medicare, complete the following, staple them together and send with the specimen:

- Patient Demographics and Third Party Billing Information form (required)
- Advanced Beneficiary Notice of Noncoverage (ABN) form (required see separate ABN form: MC2934-340)
- Copy of front and back of secondary insurance card (if applicable)

Attach the ABN form and copy of the secondary insurance card to the Patient Demographics and Third Party Billing Information form and send with the specimen.

Note: The Letter of Medical Necessity and a copy of the Medicare card are not required for Medicare-covered patients.

Medicaid

Mayo Clinic Laboratories may be able to file claims for your Medicaid-covered patients. Before ordering, contact the MCL Business Office at 800-447-6424 to discuss. Have the patient's Medicaid information available when calling.

Note: These instructions are subject to change at any time. Call the MCL Business Office at 800-447-6424 with any questions.



Prior Authorization Patient Demographics and Third Party Billing Information

Patient Demographics and Insurance	e Information			
Patient Name (Last, First Middle)			Birth Da	te (mm-dd-yyyy)
Sex Assigned at Birth		Legal/Administrative Sex		
☐ Male ☐ Female ☐ Unknown ☐ Choose not to disclose		☐ Male ☐ Female ☐ Nonbinary		
Patient Mailing Address		City	State	ZIP Code
Primary Insurance Company Name	Insurance Subscrib	er ID No. / Policy No.	Insurance Group	No. (if applicable)
Primary Insurance Company Mailing Address		City	State	ZIP Code
Primary Insurance Company Phone	Subscriber Name (i	Subscriber Name (if different than patient) and Relationship to Patient		
Order Information				
MCL Test ID	Test ID Name of desired MCL test			
MCL lest ID	Name of desired M	CL test		
OIBFG		CL test e <mark>rfecta and Bone Fragi</mark>	ity Gene Panel, V	aries
	Osteogenesis Impe			aries on Date (mm-dd-yyyy)
OIBFG	Osteogenesis Impe	erfecta and Bone Fragi		on Date (mm-dd-yyyy)
OIBFG ICD-10 Codes (use number codes to highest sp Referring Provider Name (Last, First)	Osteogenesis Imperiority)	erfecta and Bone Fragi	Service/Collecti	on Date (mm-dd-yyyy)
OIBFG ICD-10 Codes (use number codes to highest sp Referring Provider Name (Last, First)	Osteogenesis Imperiority)	Referring Prov	Service/Collecti	on Date (mm-dd-yyyy)
OIBFG ICD-10 Codes (use number codes to highest sp Referring Provider Name (Last, First) Client Account and Client Contact In	Osteogenesis Imposecificity) nformation	Referring Prov	Service/Collecti vider's National Pr	on Date (mm-dd-yyyy)
OIBFG ICD-10 Codes (use number codes to highest sp Referring Provider Name (Last, First) Client Account and Client Contact In MCL Client Account Number (if known)	Osteogenesis Imposecificity) nformation	Referring Prov	Service/Collecti rider's National Pr	on Date (mm-dd-yyyy)
OIBFG ICD-10 Codes (use number codes to highest sp Referring Provider Name (Last, First) Client Account and Client Contact In MCL Client Account Number (if known) Contact Name	Osteogenesis Imperoccificity) Information Referring Client Face	Referring Proving Prov	Service/Collecti rider's National Pr	on Date (mm-dd-yyyy)

Page 2 of 4 MC7226-53rev1224

Letter of Medical Necessity for Osteogenesis Imperfecta and Bone Fragility Gene Panel (OIBFG) Testing Patient Name (Last, First Middle) Birth Date (mm-dd-yyyy) Member Number Group ICD-10 Codes To Whom It May Concern: We are requesting preauthorization for the Osteogenesis Imperfecta and Bone Fragility Gene Panel, Varies (OIBFG) performed by Mayo Clinic Laboratories for (insert patient name) Patient's personal medical history is significant for Patient's family history is significant for Due to the patient's medical history, a diagnosis of osteogenesis imperfecta (OI) or other bone fragility condition is suspected,

and genetic testing is recommended.

Rationale: The use of genetic testing to aid in the diagnosis of OI is supported by experts in the field. Test results will have a direct impact on this patient's medical management, screening, and prevention of potential complications.

There are several types of OI caused by variants in several different genes, as well as several conditions leading to bone fragility that have significant clinical overlap with OI. Genetic testing is used to confirm a diagnosis and/or identify at-risk individuals. This testing would allow for the unequivocal diagnosis of a genetic variant causative of the patient's medical history, and would have significant implications for the patient's clinical management regarding decision-making and medical management. For example, identification of a disease-associated variant would confirm a diagnosis of OI or a related condition, and warrant appropriate orthopedic interventions, dental treatment, hearing loss evaluation, and pharmacologic treatment which may reduce or prevent complications, including fractures. In summary, a positive genetic test result would provide a definitive cause for this patient's medical history and would ensure this patient is being treated appropriately.

A negative genetic test result could also be informative. A negative result may help to reinforce that the patient does not have OI or other bone fragility disorder or, alternatively, it could indicate that additional genetic testing (such as whole exome or whole genome sequencing) should be considered to confirm an alternate diagnosis and allow for gene-specific management and screening.

Genetic testing can confirm a diagnosis of heritable OI, and a positive result may mean family members are at up to a 50% risk of being affected, or of being a carrier for OI or other bone fragility disorder. When a familial variant has been identified, genetic testing can identify family members who are not at increased risk for OI or other bone fragility disorder. No other test can reliably differentiate unaffected family members, who do not require further health screening, from presymptomatic affected family members, who must be followed closely by appropriate specialists.

Test requested: Osteogenesis Imperfecta and Bone Fragility Gene Panel, Varies (OIBFG) is a cost-effective test that utilizes next-generation sequencing (NGS) to evaluate 25 genes for osteogenesis imperfecta (OI) and other bone fragility disorder-associated variants.

Laboratory information: Testing would be performed at Mayo Clinic Laboratories (TIN# 411346366 / NPI# 1093792350), a CAP-accredited and CLIA-certified laboratory, using 2022 CPT codes: 81406 x2, 81408 x2, 81479.

Page 3 of 4 MC7226-53rev1224

Thank you for your thoughtful consideration of our preauthorization request. We look forward to hearing back from you.
Sincerely,
Ordering Provider Name
Contact information

References

1. van Dijk FS, Byers PH, Dalgleish R, et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20(1):11-19. doi:10.1038/ejhg.2011.141

Page 4 of 4 MC7226-53rev1224

MAYO CLINIC LABORATORIES

200 First Street SW Rochester, Minnesota 55905 800-447-6424

Patient Name (First Middle Last)	MCL Order Number

Advance Beneficiary Notice of Noncoverage (ABN)

Note: If Medicare doesn't pay for Items and Services below, you may have to pay.

Medicare does not pay for everything, even some care that you or your health care provider have good reason to think you need. We expect Medicare may not pay for the Items and Services below.

Items and Services	Reason Medicare May Not Pay	Estimated Cost
OIBFG/Osteogenesis Imperfecta and Bone Fragility Gene Panel, Varies	Patient's personal and family history of cancer does not meet Medicare's medical necessity coverage criteria for this laboratory test.	\$2,600.00

WHAT YOU NEED TO DO NOW:

- Read this notice, so you can make an informed decision about your care.
- Ask us any questions that you may have after you finish reading.
- Choose an option below about whether to receive the Items and Services listed above.

Note: If you choose Option 1 or 2, we may help you to use any other insurance that you might have, but Medicare cannot require us to do this.

	•	
Options: Check only one box. We cannot choose a box for you.		
OPTION 1.	I want the Items and Services listed above. You may ask to be paid now, but I also want Medicare billed for an official decision on payment, which is sent to me on a Medicare Summary Notice (MSN). I understand that if Medicare doesn't pay, I am responsible for payment, but I can appeal to Medicare by following the directions on the MSN. If Medicare does pay, you will refund any payments I made to you, less co-pays or deductibles.	
OPTION 2.	I want the Items and Services listed above, but do not bill Medicare. You may ask to be paid now as I am responsible for payment. I cannot appeal if Medicare is not billed.	
\square option 3.	I don't want the Items and Services listed above. I understand with this choice I am not responsible for payment, and I cannot appeal to see if Medicare would pay.	
Additional Info	rmation:	

This notice gives our opinion, not an official Medicare decision. If you have other questions on this notice or Medicare billing, call **1-800-MEDICARE** (1-800-633-4227/**TTY**: 1-877-486-2048).

Signing below means that you have received and understand this notice. You may ask to receive a copy.

Signature	Date (mm-dd-yyyy)

You have the right to get Medicare information in an accessible format, like large print, Braille, or audio. You also have the right to file a complaint if you feel you've been discriminated against. Visit Medicare.gov/about-us/accessibility-nondiscrimination-notice.

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0566. The time required to complete this information collection is estimated to average 7 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Baltimore, Maryland 21244-1850.

Form CMS-R-131 (Exp. 01/31/2026)

Form Approved OMB No. 0938-0566